Somerset Trust Co Has $571,000 Stake in Pfizer Inc. (NYSE:PFE)

Somerset Trust Co lessened its position in Pfizer Inc. (NYSE:PFE) by 43.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,521 shares of the biopharmaceutical company’s stock after selling 16,475 shares during the period. Somerset Trust Co’s holdings in Pfizer were worth $571,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. Merit Financial Group LLC lifted its stake in Pfizer by 60.8% in the 4th quarter. Merit Financial Group LLC now owns 127,967 shares of the biopharmaceutical company’s stock valued at $3,395,000 after purchasing an additional 48,397 shares during the last quarter. Walker Asset Management LLC lifted its position in shares of Pfizer by 4.6% in the fourth quarter. Walker Asset Management LLC now owns 11,598 shares of the biopharmaceutical company’s stock valued at $308,000 after buying an additional 513 shares during the last quarter. Saxon Interests Inc. boosted its stake in shares of Pfizer by 5.9% during the 4th quarter. Saxon Interests Inc. now owns 9,563 shares of the biopharmaceutical company’s stock worth $254,000 after acquiring an additional 535 shares during the period. Avanza Fonder AB acquired a new position in shares of Pfizer during the 4th quarter worth approximately $15,857,000. Finally, Wealthcare Advisory Partners LLC raised its stake in Pfizer by 1.5% in the 4th quarter. Wealthcare Advisory Partners LLC now owns 155,044 shares of the biopharmaceutical company’s stock valued at $4,113,000 after acquiring an additional 2,324 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Scott Gottlieb bought 1,000 shares of the business’s stock in a transaction on Wednesday, October 30th. The shares were purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. This represents a 11.11 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 0.06% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have commented on PFE shares. Citigroup initiated coverage on shares of Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price objective on the stock. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. UBS Group cut their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Finally, Truist Financial reduced their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Pfizer Trading Down 0.7 %

PFE opened at $26.30 on Friday. The stock has a market capitalization of $149.06 billion, a price-to-earnings ratio of 35.55, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a 50-day simple moving average of $26.09 and a 200 day simple moving average of $28.00.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. During the same period last year, the firm posted ($0.17) earnings per share. The firm’s quarterly revenue was up 31.2% compared to the same quarter last year. Analysts predict that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.54%. Pfizer’s payout ratio is 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.